ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139

International Journal of Oncology

Volumn 37, Issue 2, 2010, Pages 399-412

  Chay, Doobyung ^a   Cho, Hanbyoul ^b   Lim, Beom Jin ^b   Kang, Eun Suk ^c   Oh, Yoon Jin ^b   Choi, Sun Mi ^b   Kim, Bo Wook ^b   Kim, Young Tae ^a   Kim, Jae Hoon ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

Biomarker; Cell line; Characterization; ER 60 (PDIA3); Ovarian cancer

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MESSENGER RNA; OXALIPLATIN; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT; PDIA3 PROTEIN, HUMAN; PROTEIN DISULFIDE ISOMERASE; TUMOR MARKER;

AGED; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CASE REPORT; CHEMOSENSITIVITY; COMPARATIVE STUDY; CONTROLLED STUDY; DNA MICROARRAY; ER 60 GENE; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC POLYMORPHISM; HLA TYPING; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; OVARY CANCER; PDIA3 GENE; PRIORITY JOURNAL; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT CANCER; TWO DIMENSIONAL GEL ELECTROPHORESIS; ANIMAL; BAGG ALBINO MOUSE; CULTURE TECHNIQUE; CYSTADENOMA; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CYSTADENOMA, SEROUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN DISULFIDE-ISOMERASES; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954159827     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000688     Document Type: Article

References (43)

1. American Cancer Society: Cancer Facts and Figures 2008. American Cancer Society, 2008.
2. Committe KGO: Annual report of gynecologic cancer registry program in Korea for 2004. Korean J Obstet Gynecol 50: 28-78, 2007.
3. Rapkiewicz AV, Espina V, Petricoin EF III and Liotta LA: Biomarkers of ovarian tumours. Eur J Cancer 40: 2604-2612, 2004.
4. Luborsky JL, Barua A, Shatavi SV, Kebede T, Abramowicz J and Rotmensch J: Anti-tumor antibodies in ovarian cancer. Am J Reprod Immunol 54: 55-62, 2005.
5. Shih Ie M and Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164: 1511-1518, 2004.
6. Garson K, Shaw TJ, Clark KV, Yao DS and Vanderhyden BC: Models of ovarian cancer - are we there yet? Mol Cell Endocrinol 239: 15-26, 2005.
7. Kim JH, Skates SJ, Uede T, et al: Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287: 1671-1679, 2002. (Pubitemid 34289219)
8. Cho H, Lim BJ, Kang ES, Choi JS and Kim JH: Molecular characterization of a new ovarian cancer cell line, YDOV-151, established from mucinous cystadenocarcinoma. Tohoku J Exp Med 218: 129-139, 2009.
9. Cho H, Kang ES, Hong SW, et al: Genomic and proteomic characterization of YDOV-157, a newly established human epithelial ovarian cancer cell line. Mol Cell Biochem 319: 189-201, 2008.
10. Miller SA, Dykes DD and Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215, 1988.
11. Kim YT, Nam EJ, Yoon BS, et al: Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma. Gynecol Oncol 99: 585-590, 2005. (Pubitemid 41686540)
12. Friedman LS, Ostermeyer EA, Szabo CI, et al: Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 8: 399-404, 1994. (Pubitemid 24375608)
13. Wagner T, Stoppa-Lyonnet D, Fleischmann E, et al: Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics 62: 369-376, 1999. (Pubitemid 30075166)
14. Shevchenko A, Wilm M, Vorm O and Mann M: Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68: 850-858, 1996. (Pubitemid 26101214)
15. Shibusa T, Shijubo N and Abe S: Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res 4: 1483-1487, 1998. (Pubitemid 28265232)
16. Cannistra SA: Cancer of the ovary. N Engl J Med 329: 1550-1559, 1993.
17. Jemal A, Clegg LX, Ward E, et al: Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101: 3-27, 2004.
18. Kim K, Choi S-C, Ryu S-Y, Kim JW and Kang S-B: Major clinical research advances in gynecologic cancer 2008. J Gynecol Oncol 19: 209-217, 2008.
19. Scoles DR, Pavelka J, Cass I, et al: Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT. Gynecol Oncol 104: 120-128, 2007. (Pubitemid 46075143)
20. Langdon SP, Lawrie SS, Hay FG, et al: Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 48: 6166-6172, 1988. (Pubitemid 18266818)
21. Gamzatova Z, Villabona L, Dahlgren L, et al: Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol 103: 145-150, 2006. (Pubitemid 44399802)
22. Kubler K, Arndt PF, Wardelmann E, Krebs D, Kuhn W and van der Ven K: HLA-class II haplotype associations with ovarian cancer. Int J Cancer 119: 2980-2985, 2006.
23. Legge F, Ferrandina G, Salutari V and Scambia G: Biological characterization of ovarian cancer: prognostic and therapeutic implications. Ann Oncol 16 (Suppl. 4): 95-101, 2005. (Pubitemid 43084954)
24. Press JZ, De Luca A, Boyd N, et al: Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8: 17, 2008.
25. Holden JA: Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs. Ann Clin Lab Sci 27: 402-412, 1997.
26. Mok SC, Elias KM, Wong KK, Ho K, Bonome T and Birrer MJ: Biomarker discovery in epithelial ovarian cancer by genomic approaches. Adv Cancer Res 96: 1-22, 2007.
27. Dressman HK, Berchuck A, Chan G, et al: An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25: 517-525, 2007.
28. Ouellet V, Guyot MC, Le Page C, et al: Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 119: 599-607, 2006. (Pubitemid 43955714)
29. Bloom GC, Eschrich S, Zhou JX, Coppola D and Yeatman TJ: Elucidation of a protein signature discriminating six common types of adenocarcinoma. Int J Cancer 120: 769-775, 2007.
30. Helleman J, Jansen MP, Span PN, et al: Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 118: 1963-1971, 2006.
31. Anand S, Penrhyn-Lowe S and Venkitaraman AR: AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to taxol. Cancer Cell 3: 51-62, 2003.
32. Lei M: The MCM complex: its role in DNA replication and implications for cancer therapy. Curr Cancer Drug Targets 5: 365-380, 2005.
33. Bratt T: Lipocalins and cancer. Biochim Biophys Acta 1482: 318-326, 2000.
34. Kang HC, Kim IJ, Park HW, et al: Regulation of MDK expression in human cancer cells modulates sensitivities to various anticancer drugs: MDK overexpression confers to a multi-drug resistance. Cancer Lett 247: 40-47, 2007.
35. Tanabe K, Matsumoto M, Ikematsu S, et al: Midkine and its clinical significance in endometrial carcinoma. Cancer Sci 99: 1125-1130, 2008.
36. Cho H and Kim JH: Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. J Histochem Cytochem 57: 513-521, 2009.
37. Turano C, Coppari S, Altieri F and Ferraro A: Proteins of the PDI family: unpredicted non-ER locations and functions. J Cell Physiol 193: 154-163, 2002.
38. Lewis MJ, Mazzarella RA and Green M: Structure and assembly of the endoplasmic reticulum: biosynthesis and intracellular sorting of ERp61, ERp59, and ERp49, three protein components of murine endoplasmic reticulum. Arch Biochem Biophys 245: 389-403, 1986.
39. Bennett CF, Balcarek JM, Varrichio A and Crooke ST: Molecular cloning and complete amino-acid sequence of form-I phosphoinositide-specific phospholipase C. Nature 334: 268-270, 1988.
40. Kozaki K, Miyaishi O, Asai N, et al: Tissue distribution of ERp61 and association of its increased expression with IgG production in hybridoma cells. Exp Cell Res 213: 348-358, 1994.
41. Seliger B, Wollscheid U, Momburg F, Blankenstein T and Huber C: Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. Tissue Antigens 56: 327-336, 2000.
42. Goplen D, Wang J, Enger PO, et al: Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res 66: 9895-9902, 2006.
43. Bernardini M, Lee CH, Beheshti B, et al: High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia 7: 603-613, 2005.